The Rhythm | Issue 18
Issue 18 | Week of 3 August 2026
No major general cardiology congress fell in this window. The week's evidence arrived through routine journal publication across JAMA, JAMA Internal Medicine, JAMA Cardiology and Circulation.
Cardiology Intelligence Briefing: the value already sitting in the system
This week's five papers share a theme: not new therapy, but better use of what cardiology already has. An SGLT2 inhibitor already familiar in heart failure was tested perioperatively against a complication that has resisted prevention for years, and cut it substantially.1 Built around a community's own traditions rather than imposed on it, a food programme changed hospital-use outcomes that diet advice alone rarely touches.2 Inside millions of chest CT scans ordered for entirely unrelated reasons sits coronary calcium that, this week's evidence shows, predicts events about as well as a dedicated cardiac scan.3 Modelled across 204 countries, the population burden of elevated LDL cholesterol keeps rising in absolute terms even as age-adjusted rates fall, because population growth and ageing have outweighed those gains.4 Twenty-five years of quantified follow-up on degenerative mitral regurgitation, meanwhile, quietly undercut the reassurance often attached to the word moderate.5
None of this is glamorous. None of it needs a new drug class, a new device or a new procedure. The common thread is that cardiology's marginal gains right now come from applying existing tools, existing scans, existing community relationships and existing follow-up data more rigorously, not from waiting for the next platform technology. That is a useful corrective for a specialty that tends to celebrate novelty over application.
The broader lesson: prevention infrastructure is often already built. The task now is to use it properly.
